Tag Archives: Veracyte

Bayer and Veracyte today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with...

Veracyte, Inc. announced today the publication of an independent study showing that the Envisia Genomic Classifier enables physicians to more confidently diagnose idiopathic pulmonary fibrosis (IPF)...

Veracyte, Inc. today announced new data that advance understanding of the frequency, positive predictive value and co-occurrence of genomic alterations that are targeted by newly available...

Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of new data demonstrating the clinical and analytical validity of its Afirma® Xpression Atlas (XA) genomic test, which is used to help guide surgery and treatment decisions for patients with likely or confirmed ...

Veracyte, Inc. announced today that it has entered into a long-term strategic collaboration with Johnson & Johnson Innovation LLC* and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic...

Veracyte, Inc. today announced that new data presented at ENDO 2018, the annual meeting of the Endocrine Society, suggest that the Afirma Genomic Sequencing Classifier (GSC) can help significantly more

Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, announced findings from a new study demonstrating the potential for the company’s in-development Envisia classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILD) ...